PD98059

Catalog No.S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

10 Customer Reviews

  • a-c, Inhibitors of BRAFV600E (PLX4032) and MEK1/2 (PD98059 or AZD6244) increase PGC1α and ID2 expression (a, b) and repress integrin expression and signalling (b, c). Cells were treated with indicated concentration of inhibitors for 6 h (a, b) or 24 h (c). d, e, PLX4032 increases the interaction between ID2 and TCF4 (d) and decreases the occupancy of TCF4 at the promoters of integrin genes (e). f–g, PGC1α and ID2 are partially required for PLX4032-mediated inhibition of invasion and metastasis. For in vitro assays (f), A375 cells were incubated with 1 μM PLX4032 for 10 h. Images represent one picture captured per membrane with the scale bar representing 200 μm. Values in a, b, e and f represent mean±s.d. of independent biological triplicates; *P<0.05 and **P<0.01 by Student's t-test  in a, b, e, f.

    Nature, 2016, 537(7620):422-427.. PD98059 purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

    effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) on SRP72 protein expression was evaluated on Jurkat cells stimulated with rhIL-1. The cells were harvested at 0,120, and 240 min, and the protein expression was verified by WB using antibodies against human SRP72, human SRP54 (nonphosphorylated SRP protein), and humanGAPDHas constitutive protein.Adecreased SRP72 expression at 10 μM and 240 min was found.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  • C, effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) was evaluated in SRP72-immunoprecipitated cell lysates. WB using anti-phosphoserine antibody showed a decreased SRP72 band when used as the inhibitor at concentrations of 1 μM at 240 min, 5 μM at 120 min, and 10 μM at 120 and 240 min (lanes 3, 5, 8, and 9). D, results were analyzed and RUA illustrated, finding significant results at 1 μM at 240 versus 0, 5 μM at 120 versus 0, and 10 μM at 120 versus 0 min.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

    We used real time RT-PCR to investigate the effects of PD98059 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  •  

    Activation of a TLR2eERK1/2 pathway in MDDC. (C) MDDC were either untreated or treated with C. pneumoniae alone or in the presence of the ERK1/2 inhibitor PD98059 for 48 h. IL-12p70 and IL-10 release in culture media was assessed by ELISA. (D) MDDC were treated as in panel C for 48 h and then cocultured with purified allogeneic CD3t T cells. On day 12, supernatants were collected, and secreted cytokines were measured by ELISA.

    Microbes Infect 2013 15, 105-14. PD98059 purchased from Selleck.

    HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).

    Biochem Biophys Res Commun, 2016, 474(2):330-7.. PD98059 purchased from Selleck.

  • Collagen I and α-SMA are conducive for S. aureus adhesion to and invasion into BMFBs. BMFBs were treated with PD98059 2 h before the addition of 5 ng/ml TGF-β1; 24 h later, the adhesion (A) and invasion (B) assays were performed as previously described. The results are expressed as the mean cfu/ml ± SD from experiments performed in triplicate (*P < 0.05, **P < 0.01).

    Microb Pathog, 2017.. PD98059 purchased from Selleck.

    After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of  PD98059 for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.

     

    2010 Dr. Zhang of Tianjin Medical University. PD98059 purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Features Does not inhibit c-Raf phosphorylated MEK1.
Targets
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 Ml7OSpVv[3Srb36gRZN{[Xl? MlfONlUh|ryP MUGxJIg> MoniZox2dnS|IITo[UBDY2GfUD3pcoR2[2WmIHnuZ5Jm[XOnIHnuJJBpd3OyaH:tR4hsOSCjbnSgdIhwe3Cqbz3FVmsh\XiycnXzd4lwdg>? MXWyOVc3QTF6MR?=
MCF-7  NHHy[pNHfW6ldHnvckBCe3OjeR?= M4D6[VExKM7:TR?= NYTNS4IyOSCq NXi3PFBScW6qaXLpeJMhUUxvMUit[Y5p[W6lZXSgZ4VtdCCvaXfyZZRqd25? MWCyOVczPzBzMR?=
HepG2  MkHrSpVv[3Srb36gRZN{[Xl? Mkn6NVAh|ryP NUTzNXZCPSCq M3rLUoJtd2OtczDwbI9{eGixconsZZRm\CCPQWDLd{BqdmS3Y3XkJIJ6KGW6b3flco92eyCWR1[t{tIy NVXNToZKOjV3NkC0PFg>
HepG2  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuwb5VSOjBizszN MWCyOEBp M1PrTJN2eHC{ZYPz[ZMhXEeILd8yNU1qdmS3Y3XkJINmdGxicILvcIln\XKjdHnvckBidmRiaX72ZZNqd25? M4X3VlI2PTZyNEi4
MDA-MB-231 MWDGeY5kfGmxbjDBd5NigQ>? MlHPNlUh|ryP NEDkV4MzNTNiaB?= Mlzl[IVkemWjc3XzJJAuTVKNMT:yJIFv\CCVMUCwRVQh\XiycnXzd4lwdg>? MmjNNlU2PTV6N{W=
SW480 Mni3SpVv[3Srb36gRZN{[Xl? NUDHT2lZOjEEoN88US=> MV2xxsBp NGPYbJpz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGFVTjNicILveIVqdg>? NUf2fGJUOjV2NEe4NVY>
HCT-15 MoDRSpVv[3Srb36gRZN{[Xl? NGCyc4UyKGh? M4HJeYF1fGWwdXH0[ZMhWEeHMj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdovDqA>? MYWyOVQ{OTR{NR?=
HCT-15 MkW1RZBweHSxc3nzJGF{e2G7 M2ft[|EhcA>? M3vD[IFjd2yrc3jld{B1cGVicILveIVkfGm4ZTDl[oZm[3S|IH;mJHBITTMEoHHnZYlve3RiY4XyZ5VucW5vaX7keYNm\CCjcH;weI9{cXN? NVLSOYllOjV2M{G0NlU>
786-O NXHmOZE2SXCxcITvd4l{KEG|c3H5 NYrpNW9WPTEEoN88US=> NVP6UW52OjRiaB?= NGXaRoFxd3SnboTpZZRme8LidHjlJJBzdy2jcH;weI91cWNiZX\m[YN1eyCxZjDORy=> MkDZNlQ2ODh2N{[=
A498 NWrBb4ZLSXCxcITvd4l{KEG|c3H5 NUnTXGs{PTEEoN88US=> NH7Qe5AzPCCq M13xVZBwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D NFu0UmozPDVyOES3Oi=>
NHBE MlTaSpVv[3Srb36gRZN{[Xl? MVGyM|IxKM7:TR?= MkO4NkBp M4rrdIF1fGWwdXH0[ZMhUUxvM{Ogd5RqdXWuYYTl[EBEYEOOOD;JUE05KHOnY4LleIlwdg>? NH\iWW0zPDR5OUWyOi=>
A375 NGTQRVZE\WyuIFnueoF{cW:wIFHzd4F6 Mny5NVDjiJN{MDFCuW0> M3PwSlI1KGh? NFrQW25z\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25? M4XxfVI1PDZ4MEO2
HBMEC NGPvSoJHfW6ldHnvckBCe3OjeR?= M13hZVExKM7:TR?= MlrTNUBp MUjicI9kc3NiVlXHSk1qdmS3Y3XkJGVxcEF{IHX4dJJme3Orb36= MkfHNlQ1PTh7OEK=
HPAEpiCs  NInrUmFHfW6ldHnvckBCe3OjeR?= MXizNEDPxE1? M3viVFEhcA>? MkTVbY5pcWKrdIOgWG5HNc7zIIP0bY12dGG2ZXSgdFQzN3B2NDDNRXBMKHCqb4PwbI9zgWyjdHnvci=> NYrUSpAyOjR2NEG4O|A>
BeWo NVjhXllSTnWwY4Tpc44hSXO|YYm= NVrSXVBHOTEEoN88US=> NU\BeZdWOiCq NUPD[5RvcW6qaXLpeJMhTVKNMT:y NVLHSYdGOjR2M{O4OFY>
PC3  MV3BdI9xfG:|aYOgRZN{[Xl? M2mxO|UxKM7:TR?= MVywMlUhcA>? MX\pcohq[mm2czDNTHkuPDR7LXnu[JVk\WRiYYDvdJRwe2m|wrC= MkHQNlQ1OjR6OEm=
HGC-27 MmHuRZBweHSxc3nzJGF{e2G7 NWK3PIl7OSEEtV2= NE\oRYEyKGh? MnLTd5VxeHKnc4Pld{BTSURyMEGgdIx2eyCPSz2yNlA3NWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MVmyOFQyPjN2OR?=
MCF-7 M4\JNGZ2dmO2aX;uJGF{e2G7 NF7zTFkyOMLizszN MWOxNE8{OCCvaX6= MmO5doVlfWOnczD0bIUhXVSSLXTldIVv\GWwdDDFVmsheGixc4Doc5J6dGG2aX;u MkjLNlQ{QTB6MUm=
HUVECs M3LsVWZ2dmO2aX;uJGF{e2G7 Mnm4NVDDqM7:TR?= MUWxJIg> NXHNR|k4cW6qaXLpeJMhfGinIFjEUEBz\WS3Y3XkJGNQYC1{IHX4dJJme3Orb36gZY5lKFCJST2yJJJmdGWjc3W= NUXGN|JzOjR|OEWxNFk>
HeLa MYrGeY5kfGmxbjDBd5NigQ>? M3LwO|UxKM7:TR?= NGjoO2MxNjViaB?= MVficI9kc3NiVGLYMVEhdnWlbHXhdkBucWe{YYTpc44h[W6mIGTYUmlRKGSxd36tdoVofWyjdHnvci=> MVWyOFM4Pjh{Nx?=
HL-60  MmmwSpVv[3Srb36gRZN{[Xl? NVnLVmh1OTBxMkCg{txO MnvoNUBp NWTITVVOcW6qaXLpeJMhfGinwrDOMkBkcGmwZX7zbZNmgHS{YXP0xsBqdmS3Y3XkJIRq\m[ncnXueIlifGmxbjDpcpRwKGe{YX71cI9kgXSncx?= M4DocVI1OzV5MEKw
HL-60 MWrGeY5kfGmxbjDBd5NigQ>? NX3RRWhTOiEEtV2= MVGxOkBp NIj2dnFFVVOR M1jaXIlvcGmkaYTzJJRp\SCjc4PvZ4lifGmxbjDv[kBxWzZ{MTDSZYYuOSCjbnSgUmZCXGN|LDDhcoQhfGinIGLBMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJI52[2ynYYKgUmZCXGN| Ml;PNlQ{OzByNki=
HEK 293 MVTGeY5kfGmxbjDBd5NigQ>? MV:xNEDPxE1? NHv4cI02KGh? NVrJfHpiTE2VTx?= MVTpcohq[mm2czDXcpQucW6mdXPl[EDPui2lYYTlcolvN1SFRkSgZYN1cX[rdImgZY5lKG63Y3zlZZIh|rJvY3H0[Y5qdiCjY3P1cZVt[XSrb36= NGXWZmMzPDN{NEO2Oi=>
HEK 293 MVLGeY5kfGmxbjDBd5NigQ>? NFrhTYgyOCEQvF2= M1HKeVUhcA>? M{fQeWROW09? NH\SXoR{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk> NEjkWlIzPDN{NEO2Oi=>
SW480 M3nzS2Z2dmO2aX;uJGF{e2G7 NGfOT4MyOCEQvF2= NUDrV3JyOjBiaB?= MWTEUXNQ NXPnZWZXe3WycILld5NmeyC2aHWgR3JVKGGldHn2bZR6 MYKyOFMzPDN4Nh?=
HCSMCs NHvKWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XEWFExKM7:TR?= M{npVFI1KGh? M3G3RYJtd2OtczDGRWJRPC2rbnT1Z4VlKEiFQWPNR{Bxem:uaX\ldoF1cW:w M4exV|I1OzF{M{ix
PANC-1 MWXGeY5kfGmxbjDBd5NigQ>? NFHnPVAzOCEQvF2= NEnWZ3o1QCCq NVyycmNGcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yh|pR4RDDpckBz\XOyb37z[UB1dyC2aHWgVHBCWs72wrDh[49vcXO2wrC= M4TVWlI1Ojl2MUOz
A549 NF\TR3hHfW6ldHnvckBCe3OjeR?= MonyN|Ah|ryP NFWwSGUxNjViaB?= M3\MWGROW09? NXXsclNxcW6qaXLpeJMhfGinIITodo9u[mmwLXnu[JVk\WRiSVytPE9EYEOOOD3MeYMh[WO2aY\peJk> MXiyOFI4PzZ7Nh?=
A549 NI\HRmVHfW6ldHnvckBCe3OjeR?= MmXaN|Ah|ryP NXL4SWp5OC53IHi= NIHEWGVFVVOR NIXFbnZqdmirYnn0d{B1cHKxbXLpck1qdmS3Y3XkJGMwTUKSzsKgWIhzOjN3wrDwbI9{eGixconsZZRqd25? M3OyWFI1Ojd5Nkm2
MC-3 MXzBdI9xfG:|aYOgRZN{[Xl? MkfuNVAh|ryP NWPRTHpyOjRiaB?= MVLwc5RmdnSrYYTl[EBOTVOFLXnu[JVk\WRiYYDvdJRwe2m|IHnuJEBk\Wyucx?= NWnQSmcxOjR{N{C1NlM>
Raji  MljFSpVv[3Srb36gRZN{[Xl? MWKxNEDPxE1? NI[yNIQyKGh? M2XaPIJtd2OtczDod2JCTkZiaX7keYNm\CCHcnuxM|IheGixc4Doc5J6dGG2aX;u MWCyOFI3QTZ|MB?=
Raji  NIfvfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjVZmJMOTBizszN MWixJIg> M{f0TIlvcGmkaYTzJJRp\SCkYYPhcEBweiCqc1LBSmYue3SrbYXsZZRm\CClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fS=> MlXmNlQzPjl4M{C=
HT29 MUPGeY5kfGmxbjDBd5NigQ>? NUnyU5N[OTBizszN M4fJbVIhcA>? MmL1bY5pcWKrdIOgc4YhUkGNMjygSXJMOS9{IHHu[EBUXEGWMzDwbI9{eGixconsZZRqd25? NFjQeGMzPDJ4NUK5Ny=>
HepG2 NVXUSJFjSXCxcITvd4l{KEG|c3H5 NXn1So55OjBizszN NWTZfINSOjRiaB?= M4XxdIlvcGmkaYTzJGVTUzFxMjDwbI9{eGixconsZZRqd25iYX7kJIVvcGGwY3XzJHZDOS2rbnT1Z4VlKGGyb4D0c5Nqew>? MoTVNlQzPDd7MEm=
HepG2 NGn6T2JHfW6ldHnvckBCe3OjeR?= NUf5NIF5OjBizszN Ml3RNkBp NUn2WoJY\W6qYX7j[ZMhXkJzLXnu[JVk\WRiRl;YU|NiKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fS=> NUnwTZdlOjR{NEe5NFk>
TE4 NGH3TJpHfW6ldHnvckBCe3OjeR?= NX7MdHJ3OjBxNUCvNVAxKM7:TR?= MmrDOFghcA>? Ml6wSG1UVw>? M1i3TIlvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWqyOFI1PDB{Mx?=
TE1 M{\zTWZ2dmO2aX;uJGF{e2G7 MYmyNE82OC9zMECg{txO MXW0PEBp MnO2SG1UVw>? MmnJbY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoKxNlQzPDRyMkO=
KYSE30 MWPGeY5kfGmxbjDBd5NigQ>? M2PV[VIxNzVyL{GwNEDPxE1? Mkf2OFghcA>? NE\KUXJFVVOR MWPpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmLZNlQzPDRyMkO=
TE1 MXzGeY5kfGmxbjDBd5NigQ>? NWS5NWk5PTBizszN M3\5XlQ5KGh? Mki0SG1UVw>? MmjCeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? MlftNlQzPDRyMkO=
TE3 NYHW[VlXTnWwY4Tpc44hSXO|YYm= M3LWflUxKM7:TR?= M1vTSFQ5KGh? NUK5cWF4TE2VTx?= MVv1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? NU\tPYUzOjR{NESwNlM>
TE4 NHnJZ5RHfW6ldHnvckBCe3OjeR?= MojXOVAh|ryP M4HvVFQ5KGh? MkXISG1UVw>? MXv1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? MWGyOFI1PDB{Mx?=
TE5 Ml7xSpVv[3Srb36gRZN{[Xl? M3XvbVUxKM7:TR?= NXXnVYVRPDhiaB?= NYjFT21OTE2VTx?= NF\3Vll2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKTFGgZ4xie3NiSR?= NITyPWczPDJ2NECyNy=>
KYSE30 M1LZWGZ2dmO2aX;uJGF{e2G7 MVW1NEDPxE1? NWmzbVRnPDhiaB?= M17YUGROW09? NV3YbHRzfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= MXuyOFI1PDB{Mx?=
MKN7 MUPGeY5kfGmxbjDBd5NigQ>? MnHvOVAh|ryP NHfjbWs1QCCq MmPMSG1UVw>? NVviTm1HcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> NX3aNFFrOjR{NESwNlM>
OE19 NIrNOJJHfW6ldHnvckBCe3OjeR?= MUi1NEDPxE1? MXG0PEBp NIXCRY1FVVOR NV\UWWRicW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> MVOyOFI1PDB{Mx?=
KATOIII  MlvuSpVv[3Srb36gRZN{[Xl? MoG1OVAh|ryP M2HxN|Q5KGh? Ml3XSG1UVw>? NXXCZlFJcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> M2jrflI1OjR2MEKz
NCI-N87  MWDGeY5kfGmxbjDBd5NigQ>? M2n0TVUxKM7:TR?= MYS0PEBp NH:2NZRFVVOR M{XDd4lv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO= M2jBZVI1OjR2MEKz
NUGC3 Ml7pSpVv[3Srb36gRZN{[Xl? M2\NXVUxKM7:TR?= NEDMUmE1QCCq MWTEUXNQ NFfF[3FqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz MViyOFI1PDB{Mx?=
NUGC2 NEPMVVRHfW6ldHnvckBCe3OjeR?= M3;0NlUxKM7:TR?= M1TCNlQ5KGh? MkHHSG1UVw>? NVj3V2FwcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> NIL6PHczPDJ2NECyNy=>
SGC-7901  NV3CWHpkSXCxcITvd4l{KEG|c3H5 NXLzcXozOjBizszN NWjVSWd6OjRiaB?= Mn\FbY5pcWKrdIOgR3AudWWmaXH0[YQh[XCxcITvd4l{ NYnqNZFVOjR{NEGzOVE>
MG-63 MUTGeY5kfGmxbjDBd5NigQ>? MoL6NlAh|ryP MlLYNE42KGh? M1LxS4Jtd2OtczD0bIUhS0hvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBGVEtzIIDyc5RmcW5iZYjwdoV{e2mxbh?= M1f1R|I1OjN7NkSw
ARPE-19 M3z6ZWZ2dmO2aX;uJGF{e2G7 MViyNEDPxE1? NWj1U4s3OC53IHi= NIGzcWNqdmirYnn0d{BCeGWuaX6tbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gSZJsKGGwZDDBb5Q> MmDjNlQzOjd7MUi=
CRL-2302 NFPxU5JHfW6ldHnvckBCe3OjeR?= MnXpNlAh|ryP MXOwMlUhcA>? MlnRbY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0 NHPrb2szPDJ{N{mxPC=>
MCF-7 MU\GeY5kfGmxbjDBd5NigQ>? MmSyNlAh|ryP MX2xJIg> M4XiR4Fjd2yrc3jld{BmgHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIVlKEWUSzDjc{11emWjdH3lcpQhf2m2aDDjc45rfWejdHW= MWGyOFIyPjJ6OR?=
MCF-7 MnfHRZBweHSxc3nzJGF{e2G7 NF;rVVgzOCEQvF2= M3vscFEhcA>? MVnpcoNz\WG|ZYOgZ4F{eGG|ZT25JIVvgnmvZTDhZ5Rqfmm2eR?= MUWyOFIyPjJ6OR?=
DLD-1  MYrGeY5kfGmxbjDBd5NigQ>? NXTrcVg{OjEEoN88US=> NVTRNJBMPDhiaB?= MlPYdoVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD MVyyOFIyOTV6MR?=
HT-29 M{XuPWZ2dmO2aX;uJGF{e2G7 NXfBXnF1OjEEoN88US=> NIjk[2s1QCCq MkTkdoVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD NH3KUIszPDJzMUW4NS=>
7402 NYL2TYExSXCxcITvd4l{KEG|c3H5 NV\1V|Y4OzBizszN MUe1JIQ> M4P1SoRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> M3LVbFI1OjFzMkWz
7721 M3TWZWFxd3C2b4Ppd{BCe3OjeR?= MnLUN|Ah|ryP MYi1JIQ> M1n0NYRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> MoDzNlQzOTF{NUO=
SGC7901  NV\6WHU{SXCxcITvd4l{KEG|c3H5 M1zWWlUxyqEQvF2= NHv4ZXEzPC92OD:3NkBp NYDpcIRTTE2VTx?= M4jxUIlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSlHLNkB{cFKQQR?= MXiyOFE4QDJ2MB?=
SMMC7721 NFfjRYpHfW6ldHnvckBCe3OjeR?= MnjBNlUwPTBizszN MkD5NlQhcA>? NX3TSJZke3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCyLVHreEBweiCyLVXST|EwOsLi M1HWdVI1OTZ6MEW2
MCF-7 NH;lb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjab4YyOCEQvF2= NXTKTZRFPDiq NVzMVJhCTE2VTx?= M1PqbpJmfmW{c3XzJGJPTi2rbnT1Z4VlKGOnbHygZ5lkdGViYYLy[ZN1 NF:5eGUzPDF4M{SwOC=>
Caco-2 M4XDR2Z2dmO2aX;uJGF{e2G7 MVy1NOKh|ryP Mm[5OFhp NXLlOGVqTE2VTx?= M{jPWYVvcGGwY3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhW0OQTkHBMGZZYUR|LNMgUGNVNMLiTF;YMOKhUEmIM1GsxsBbTzF4LNMgVGRGPkIEoHHu[OKhVEeDTGOxOuKh\2WwZYRCpINwNXS{ZXH0[YQhf2m2aDDE[Zg> NWT5fXlwOjRzNkG2PVU>
HAECs MV\GeY5kfGmxbjDBd5NigQ>? MoTiNVAh|ryP NVPqV5VzOSCq NFnTdnPDqGG2dHXueYF1\XNiVF7GMe6yNXO2aX31cIF1\WRiSVPBUU0yKGGwZDDWR2FONTFiZYjwdoV{e2mxbh?= NUOxTIZVOjRzM{S2OVc>
Ca9-22 MmnHSpVv[3Srb36gRZN{[Xl? NUfhd3RoOyEQvF2= MkLhNUBp MYThZo9tcXOqZYOgeIhmKGGkaXzpeJkhd2ZiSHLSJJRwKGmwZIXj[UBKVC16IIDyc4R2[3Srb36= NHHrPIUzPDF{NkWzNi=>
Ca9-22 NXzkcGd{TnWwY4Tpc44hSXO|YYm= M2nLfVMh|ryP NGPJfHcyNzJiaB?= NECwb4Jz\WS3Y3XzJGhjWi2rbnT1Z4VlKEGWRj2yJJBpd3OyaH;yfYxifGmxbh?= NVXQNoY1OjRzMk[1N|I>
AGS MofxSpVv[3Srb36gRZN{[Xl? M{Tjb|ExKM7:TdMg M3O0TVAvPSCq MkLGbY5pcWKrdIOgeIhmKHWycnXneYxifGmxbjDv[kB1cGViSVytPEBo\W6n MnHmNlQyODZzNk[=
Caco-2  NEDBRVFCeG:ydH;zbZMhSXO|YYm= MoXJNVDDqM7:TR?= NE\ZUI0zPMLiaB?= M3uwN4Rm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV? M3vpWVI1ODl3OE[z
HCT-8 MmraRZBweHSxc3nzJGF{e2G7 MX2xNOKh|ryP M2nX[VI1yqCq MWjk[YNz\WG|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTC1MWZW MXeyOFA6PTh4Mx?=
A549 Mnn5SpVv[3Srb36gRZN{[Xl? MnG2OVDDqM7:TR?= NU\jT3o2OiCq NXjSS|RX[myxY3vzJGVTUyCyaH;zdIhwenmuYYTpc44hdWWmaXH0[YQh[nliMTyyMW5S NHrGSIozPDB4N{eyOy=>
HPMC MmDESpVv[3Srb36gRZN{[Xl? MnTsNVDDqM7:TR?= MlvGOFghcA>? MlzydoV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iY3XscEBud3KyaH;sc4d6KGmwZIXj[YQh[nliSFfQSHM> NEHh[|QzPDB2MkizPC=>
HPMC Mn\KRZBweHSxc3nzJGF{e2G7 NUXPXGdWOTEEoN88US=> MVKyOOKhcA>? MWry[ZZmenOnczDk[YNz\WG|ZTDpckBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JGhIWESV NVj2R5dTOjRyNEK4N|g>
MGC803  Mn\HRZBweHSxc3nzJGF{e2G7 MnXKNlDDqM7:TR?= NHXZS4oyKGh? NHvyTHZqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCLRl6t{tHDqGGwZDC15qCzNUSIVWK= MV2yOFAzPzd3MB?=
SGC7901 NFj0NVhCeG:ydH;zbZMhSXO|YYm= M1LJ[lIxyqEQvF2= Mlf2NUBp M1XOc4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?= M3r3VVI1ODJ5N{Ww
COLO205 MX;BdI9xfG:|aYOgRZN{[Xl? NEHGSXMyOC9{MD:0NEDPxE1? MnPINlQhcA>? MXPpcoR2[2W|IFTORUBt[WSmZYKg[o9zdWG2aX;u NF24XWEzPDBzOUGwPC=>
G292  Mn\vRZBweHSxc3nzJGF{e2G7 MYizNOKh|ryP MmLCNkBp M1;qZpJme3SxcnXzJINieHOjaXPpck1qdmS3Y3XkJINmdGxiZHXheIg> M3GzblI1ODF{OUOw
BxPC-3 Moq0SpVv[3Srb36gRZN{[Xl? MVKxNEDPxE4EoB?= NF:3RY83KGh? M{fCTolv[3KnYYPlJI1qWi1zNEOg[ZhxemW|c3nvci=> MXuyN|k4OzdzMB?=
HPAF-II NUnJN2M6TnWwY4Tpc44hSXO|YYm= M1vvfFExKM7:TdMg MYS2JIg> Ml7ObY5kemWjc3WgcYlTNTF2MzDlfJBz\XO|aX;u MlvpNlM6PzN5MUC=
HL-60 NEf4UYVCeG:ydH;zbZMhSXO|YYm= M4DmdFUxyqEQvF2= MVGxJIg> MVry[ZNkfWW|IFLBNVQ2KG2nZHnheIVlKGGyb4D0c5Nqew>? M{nO[FI{QTR6N{Wx
HepG2 MVfGeY5kfGmxbjDBd5NigQ>? M4DMbFQxKM7:TR?= NVjFfFZ7Pi9zMjDo NVXSR|lscW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJAuTVKNMTDhcoQheC2lLVr1ckBxem:2ZXnuJIV5eHKnc4Ppc44h[nliUFy= MnXQNlM6PDJ6NUG=
HUVECs NGXiWoRHfW6ldHnvckBCe3OjeR?= MVyyOUDPxE1? Ml\aNUBp NYXXV4h6cW6lcnXhd4UhVkZvzsrCJJA3PSCwdXPs[YFzKHS{YX7zcI9k[XSrb36= M1jPV|I{QTBzMEC4
LNCaP  MUPGeY5kfGmxbjDBd5NigQ>? NHrWc|AyOCEQvF5CpC=> MkHWNUBp Mlrx[IVkemWjc3XzJJRp\SCHR1[geZBz\We3bHH0[YQheC2\Qj2x NX32e2Q3OjN6M{izNVg>
HL60  MVfGeY5kfGmxbjDBd5NigQ>? MYSyNOKh|ryP MojFO|IhcA>? MYrEUXNQ NFTzWHZqdmirYnn0d{Bl[XOjdHnubYIucW6mdXPl[EBETDFzYjDlfJBz\XO|aX;u NEfHRZYzOzh{NUW4OS=>
NB4  MmPVSpVv[3Srb36gRZN{[Xl? MUmxNEDPxE4EoB?= NIfoNWw4OiCq MUDEUXNQ Mn7QbY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?= MUGyN|gzPTV6NR?=
EPOR/CR3 M4izOGZ2dmO2aX;uJGF{e2G7 M4T5R|UxyqEQvF2= MnS2N{Bp NUn3OWNwemWmdXPld{BGWE9iYX7kM49zKEmOLUOtbY5lfWOnZDD0bIUhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uxsA> M{fkNFI{QDJyN{Ox
HUASMCs NF7PcoJHfW6ldHnvckBCe3OjeR?= M4PQTlExKM7:TdMg NYq0T|dLOjRiaB?= MWDkbY1qdmm|aHXzJGFv\yCLST3jZZV{\WRiU1;DV|MhdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vyqB? NIDCdnUzOzhzNkS2PC=>
HUASMCs NUXZS5ZUTnWwY4Tpc44hSXO|YYm= MlvVNVAh|ryPwrC= M3LxWFI1KGh? M13NPYlvcGmkaYTzJGFv\yCLST3pcoR2[2WmIFXST|EwOiCyaH;zdIhwenmuYYTpc44hdGW4ZXy= MWiyN|gyPjR4OB?=
SGC7901 MWjGeY5kfGmxbjDBd5NigQ>? M2HsflExKM7:TdMg M1r5T|I1KGh? MUDpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM|I> M2D5blI{Pzl{NUi4
MKN45 MUTGeY5kfGmxbjDBd5NigQ>? MWmxNEDPxE4EoB?= MXeyOEBp M{O3OIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST|EwOg>? NGXEOVkzOzd7MkW4PC=>
SGC7901 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHCNVAh|ryPwrC= NHrZOHEzPC92OD:3NkBp MWTpcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>? MnfaNlM4QTJ3OEi=
MKN45 NVW2WI5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LZTlExKM7:TdMg NVTyXlZKOjRxNEivO|IhcA>? MUDpcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>? M1jVZ|I{Pzl{NUi4
SGC7901 NV:0V406SXCxcITvd4l{KEG|c3H5 M3jpXlExKM7:TdMg MoHSNlQhcA>? M{eyZ4lv[3KnYYPld{B1cGViRFHQWE1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| M{PqRVI{Pzl{NUi4
MKN45 MkewRZBweHSxc3nzJGF{e2G7 NVKwOVVQOTBizszNxsA> MWiyOEBp M4Ww[Ilv[3KnYYPld{B1cGViRFHQWE1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| NGrsUm0zOzd7MkW4PC=>
BxPC-3 cells NYD5dpRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P3WFIxyqEQvF2= NUnpfpllOC53IHi= M2PUbIlvcGmkaYTzJHZGT0ZvQT3y[Yd2dGG2ZXSgTHVXTUNiZ4Lve5RpKGGwZDD0eYJmKG[xcn3heIlwdiCrbnT1Z4VlKGK7IGDBVk0zKEGS Mke4NlM4PjRyNE[=
NB4  MnftRZBweHSxc3nzJGF{e2G7 M3vvVVExNzJyL{[wJO69VQ>? NYf2UJJmOS53IHi= M2f5bWROW09? Mn[3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2ZXSge4l1cCCSYXPsbZRigGWu MXyyN|c{PTV2MR?=
HepG2  NFjM[VNHfW6ldHnvckBCe3OjeR?= M2XL[FIxyqEQvF2= M4W1VVI1KGh? M1jkUolvcGmkaYTzJJRp\SCKTz2xJJBzd3SnaX6g[ZhxemW|c3nvckBkdy22cnXheIVlKHerdHigcYV1\m:{bXnu M{XMbFI{PzB5NkC5
HUVECs M1L2XGFxd3C2b4Ppd{BCe3OjeR?= NYq2SGx{Oi92IN88US=> MmfPNlQwPDhiaB?= M{TjfYlv\HWlZYOgZ4VtdCCmZXH0bC=> NVu3TGllOjN5MEe1NlA>
KG-1  MUjBdI9xfG:|aYOgRZN{[Xl? MmXhNlDDqM7:TR?= NFf5UY0yOiCq NYqzXppq\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBUOQ>? NYrk[21nOjN5ME[2PVE>
AML 1# MmLJRZBweHSxc3nzJGF{e2G7 NEiy[Y8zOMLizszN MYixNkBp MkXv[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=> MX6yN|cxPjZ7MR?=
A2780  M3fuSmZ2dmO2aX;uJGF{e2G7 M3ftdVIxyqEQvF2= M{OyVlEhcA>? NWjxR5N[[myxY3vzJGRVS0RvaX7keYNm\CCGUkWg[ZhxemW|c3nvci=> MYqyN|Y6Pjh4Mh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:

[1]

+ Expand
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28
Formula

C16H13NO3

CAS No. 167869-21-8
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to formulate this inhibitor for i.p. injection?

  • Answer:

    You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID